Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: MET and KRAS comutation in the same group of cells of primary tracheal adenoid cystic carcinoma is extremely rare; there is no standard of care for patient with metastatic disease.
Case Presentation: We report a 42-year-old treatment-naïve Chinese male patient with metastatic tracheal adenoid cystic carcinoma harboring a MET p.D1010Y and KRAS p.G12C comutation. The patient responded well to the MET inhibitor crizotinib and MEK inhibitor trametinib combination therapy, but had progression when he discontinued trametinib because of grade III rashes on the face and trunk. With the reintroduction of trametinib with a dose reduction, his metastatic lesions shrank after 2 months of therapy.
Conclusion: MET p.D1010Y and KRAS p.G12C comutation is extremely rare and could happen concurrently in the same group of cells of metastatic tracheal adenoid cystic carcinoma; crizotinib combined with trametinib is effective, and the toxicities are manageable.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12323115 | PMC |
| http://dx.doi.org/10.1186/s13256-025-05246-7 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Two-Scope Technique for Tracheal Epithelial-Myoepithelial Carcinoma-A Rare Case Report and Review.
Respirol Case Rep
September 2025
Core Diagnostics New Delhi India.
Epithelial myoepithelial carcinoma (EMC) is an exceptionally uncommon salivary gland type tumour of the lung accounting for only 0.1% to 1% of all primary pulmonary malignancies. We describe a 40-year-old man presenting with hemoptysis, in whom computed tomography (CT) of the chest revealed an endoluminal mass in the upper trachea.
View Article and Find Full Text PDFAdenoid Cystic Carcinoma Treated With Salvage ZAP-X Radiosurgery in Elderly Patients: A Report on a Case Series.
Cureus
August 2025
Department of Oncology, University of Warmia and Mazury in Olsztyn, Olsztyn, POL.
Management of recurrent adenoid cystic carcinoma (ACC) in elderly patients remains challenging due to comorbidities, functional impairments, and anatomically complex tumor locations that complicate surgical access and increase operative risk. The ZAP-X Gyroscopic Radiosurgery System (ZAP Surgical Systems, Inc., San Carlos, CA, USA) offers a highly precise, non-invasive treatment modality, potentially suitable for salvage therapy in previously irradiated fields and in medically inoperable patients.
View Article and Find Full Text PDFEngineered biomimetic vesicles induce cuproptosis and disrupt efferocytosis for metastatic adenoid cystic carcinoma immunotherapy.
Mater Today Bio
October 2025
Department of Stomatology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, 324 Jingwu Road, Jinan, 250021, Shandong, China.
Adenoid cystic carcinoma (ACC) is a lethal salivary gland malignant neoplasm. Lung metastasis is the primary cause of mortality in ACC patients while there is no effective treatment available at present. In this study, a precise and biomimetic nanoplatform, CG/MC/U-M, is designed to combine cuproptosis, gas therapy and immunotherapy against metastatic adenoid cystic carcinoma.
View Article and Find Full Text PDFRare hepatic metastasis in classical adenoid cystic carcinoma of the breast: A case report.
Oncol Lett
November 2025
Department of Breast Surgery, Zhuzhou Hospital Affiliated to Xiangya School of Medicine, Central South University, Zhuzhou, Hunan 412000, P.R. China.
Adenoid cystic carcinoma of the breast (ACCB) is a rare and distinct form of triple-negative breast cancer, accounting for only 0.06-0.1% of all breast cancers.
View Article and Find Full Text PDFAssociation of Programmed Death-Ligand 1 Expression in Relation to Tumor-Infiltrating Lymphocyte Concentration and Histological Type with Outcomes of Triple-Negative Breast Cancer.
J Nippon Med Sch
September 2025
Department of Breast Surgery, Tokyo Women's Medical University Adachi Medical Center.
Background: Triple-negative breast cancer (TNBC) comprises subgroups with distinct characteristics and histological types. Tumor-infiltrating lymphocyte (TIL) concentration and programmed death-ligand 1 (PD-L1) expression are prognostic factors for TNBC. We analyzed the association of immune cell PD-L1 expression, in relation to histological type and TIL concentration, with TNBC outcomes.
View Article and Find Full Text PDF